Pila Pharma AB (publ) (PILA.ST)
SEK 2.99
(1.87%)
SEK 2.99
(1.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.93 Million SEK | 77.77% |
| 2022 | -44.66 Million SEK | -77.56% |
| 2021 | -25.15 Million SEK | -137.66% |
| 2020 | -10.58 Million SEK | 16.13% |
| 2019 | -12.61 Million SEK | -125.31% |
| 2018 | -5.6 Million SEK | -17.52% |
| 2017 | -4.76 Million SEK | -220.73% |
| 2016 | -1.48 Million SEK | -65.06% |
| 2015 | -900.26 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.04 Million SEK | 0.0% |
| 2024 Q1 | -2.04 Million SEK | -57.03% |
| 2023 Q2 | -3.05 Million SEK | 50.95% |
| 2023 Q4 | -1.3 Million SEK | 14.97% |
| 2023 Q1 | -6.23 Million SEK | 77.7% |
| 2023 Q3 | -1.53 Million SEK | 49.98% |
| 2023 FY | -9.93 Million SEK | 77.77% |
| 2022 Q4 | -27.96 Million SEK | -4395.45% |
| 2022 Q2 | -10.75 Million SEK | 41.19% |
| 2022 FY | -44.66 Million SEK | -77.56% |
| 2022 Q1 | -18.28 Million SEK | -237.18% |
| 2022 Q3 | 651 Thousand SEK | 106.05% |
| 2021 Q1 | -2.46 Million SEK | 52.86% |
| 2021 FY | -25.15 Million SEK | -137.66% |
| 2021 Q4 | -5.42 Million SEK | 2.77% |
| 2021 Q3 | -5.57 Million SEK | -16.26% |
| 2021 Q2 | -4.79 Million SEK | -94.84% |
| 2020 Q3 | -294 Thousand SEK | 0.0% |
| 2020 FY | -10.58 Million SEK | 16.13% |
| 2020 Q4 | -5.22 Million SEK | -1676.45% |
| 2019 FY | -12.61 Million SEK | -125.31% |
| 2018 FY | -5.6 Million SEK | -17.52% |
| 2017 FY | -4.76 Million SEK | -220.73% |
| 2016 FY | -1.48 Million SEK | -65.06% |
| 2015 FY | -900.26 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 78.319% |
| Biovica International AB (publ) | -124.82 Million SEK | 92.045% |
| Cantargia AB (publ) | -280.02 Million SEK | 96.454% |
| CombiGene AB (publ) | -35.66 Million SEK | 72.158% |
| Cyxone AB (publ) | -22.98 Million SEK | 56.805% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 14.968% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 39.444% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 89.136% |
| Fluicell AB (publ) | -26.55 Million SEK | 62.604% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 91.931% |
| Mendus AB (publ) | -101.61 Million SEK | 90.228% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 73.214% |
| I-Tech AB | 20.2 Million SEK | 149.151% |
| Intervacc AB (publ) | -102.85 Million SEK | 90.345% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 18.123% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 181.601% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 44.516% |
| OncoZenge AB (publ) | -15.9 Million SEK | 37.555% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -2167.125% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 97.442% |
| Lipum AB (publ) | -37.17 Million SEK | 73.291% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 96.005% |
| Ziccum AB (publ) | -21.41 Million SEK | 53.624% |
| BioArctic AB (publ) | 229.24 Million SEK | 104.332% |
| Genovis AB (publ.) | 61.5 Million SEK | 116.146% |
| Camurus AB (publ) | 431.44 Million SEK | 102.302% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 94.416% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 82.524% |
| Aptahem AB (publ) | -11.11 Million SEK | 10.644% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 96.806% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 94.473% |
| Kancera AB (publ) | -64.88 Million SEK | 84.697% |
| Saniona AB (publ) | -95.81 Million SEK | 89.636% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 76.482% |
| AcouSort AB (publ) | -17.08 Million SEK | 41.892% |
| Xintela AB (publ) | -54.08 Million SEK | 81.639% |
| Abliva AB (publ) | -95.5 Million SEK | 89.603% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 284.367% |
| Amniotics AB (publ) | -30.87 Million SEK | 67.833% |
| 2cureX AB (publ) | -32.51 Million SEK | 69.463% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 22.591% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 97.87% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.806% |
| Biosergen AB | -27.03 Million SEK | 63.273% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 39.902% |
| Corline Biomedical AB | -1.8 Million SEK | -448.923% |
| NextCell Pharma AB | -41.95 Million SEK | 76.334% |
| Nanologica AB (publ) | -75.15 Million SEK | 86.788% |
| LIDDS AB (publ) | -40.2 Million SEK | 75.302% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 96.962% |
| BioInvent International AB (publ) | -330.3 Million SEK | 96.994% |
| SynAct Pharma AB | -215.81 Million SEK | 95.399% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 77.459% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 58.167% |
| Alzinova AB (publ) | -16.48 Million SEK | 39.745% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 90.914% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 96.014% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 91.237% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 52.918% |
| Simris Alg AB (publ) | -37.3 Million SEK | 73.382% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 93.461% |